Respiratory Biomarker Testing Devices Market

The Respiratory Biomarker Testing Devices Market is analyzed across its key biomarker analyte, clinical care location, consumable model and patient use profile segments, with the study covering market dynamics, regional trends and demand outlook, forecast 2026 to 2036.

By Fact.MR Healthcare Desk Lead analyst: S.N. Jha Updated : 11 min read Fact-checked under the Fact.MR editorial process

  • Market Value (2025): USD 278.78 Mn
  • Estimated Value (2026): USD 310.2 Mn
  • Forecast Value (2036): USD 902.4 Mn
  • CAGR (2026-2036): 11.3%

Respiratory Biomarker Testing Devices Market Forecast and Outlook 2026 to 2036

According to the Fact.MR analysis, the respiratory biomarker testing devices market crossed a valuation of USD 278.8 million and in 2025 is projected to grow from USD 310.2 million in 2026 to USD 902.4 million by 2036. Demand for respiratory biomarker testing devices is likely to grow at a CAGR of 11.3% over the forecast period.

Demand for respiratory biomarker testing devices is rising as clinicians look beyond spirometry to measure inflammation, exposure and disease signatures in breath. Manufacturers of biomarker testing devices are building platforms for volatile organic compounds, exhaled carbon monoxide, FeNO and breath condensate that support diagnosis and treatment selection. For example, Owlstone Medical has built its Breath Biopsy VOC Atlas, a catalogue of validated and quantified volatile organic compounds found on breath, to give researchers and clinicians context for breath biomarkers. Similar reference resources are projected to drive sales of respiratory biomarker testing devices.

Key Takeaways from the Respiratory Biomarker Testing Devices Market

  • Respiratory Biomarker Testing Devices Market Value (2025): USD 278.8 million
  • Respiratory Biomarker Testing Devices Market Value (2026): USD 310.2 million
  • Respiratory Biomarker Testing Devices Market Forecast Value (2036): USD 902.4 million
  • Respiratory Biomarker Testing Devices Market Forecast CAGR (2026-2036): 11.3%
  • Leading Biomarker Analyte: Breath VOC (28.1%)
  • Key Market Participants: NIOX Group, Bedfont Scientific, Eco Medics, Bosch Healthcare Solutions, Sunvou Medical Electronics, Vitalograph
  • Key Growth Regions: China, United States, Germany, United Kingdom, Japan

In September 2026, Germany's 'Decade of the Lung' initiative noted that more than 14 million people in Germany, around 16% of the population, live with chronic lung and respiratory diseases such as asthma, COPD and pulmonary hypertension. Demand for respiratory biomarker testing devices is growing because large patient populations need faster, more precise assessment than symptoms alone allow. Manufacturers of biomarker testing devices are targeting pulmonology, allergy and primary care. Similar disease burden is projected to drive sales of respiratory biomarker testing devices across Europe, North America and Asia.

Respiratory Biomarker Testing Devices Market

Metric Value
Estimated Value in (2026) USD 310.2 million
Forecast Value in (2036) USD 902.4 million
Forecast CAGR (2026 to 2036) 11.3%

Source: Fact.MR analysis. Updated Nov 20, 2026

Source: Fact.MR analysis.

Respiratory Biomarker Testing Devices Forecast Global

Respiratory Biomarker Testing Devices Forecast Global | Source: Fact.MR

Category

Category Segments
Biomarker Analyte Breath VOC, Exhaled CO, FeNO, Exhaled breath condensate, Multi-biomarker
Clinical Care Location Allergy / immunology, Pulmonology clinic, Primary care, Pediatric care, Home / remote
Consumable Model Service subscription, Disposable cartridge, Single-use mouthpiece, Calibration gas / kit, Reusable sensor
Patient Use Profile Diagnostic evaluation, Pediatric asthma, COPD, Adult asthma, Longitudinal monitoring
Region China; United States; Germany; United Kingdom; Japan

Source: Fact.MR analysis. Updated Nov 20, 2026

Source: Fact.MR analysis.

Segmental Analysis

Why does breath VOC analysis lead analyte demand in the Respiratory Biomarker Testing Devices Market?

Respiratory Biomarker Testing Devices Breakdown Respiratory Biomarker Analyte

Respiratory Biomarker Testing Devices Breakdown Respiratory Biomarker Analyte | Source: Fact.MR

Demand for breath VOC analysis accounts for 28.1% of the respiratory biomarker testing devices market in 2026, about USD 87.2 million, because volatile organic compound profiles can reflect inflammation, infection, metabolic changes and exposure in a single sample. VOC platforms are used in research programs and increasingly in clinical pathways for gut and respiratory conditions. Manufacturers of biomarker testing devices are combining sampling devices with mass spectrometry and sensor-based analysis. Similar interest in multi-marker breath signatures is projected to keep breath VOC the leading analyte, complementing tools in the COPD biomarker testing systems market.

How are allergy and immunology settings leading clinical demand in the Respiratory Biomarker Testing Devices Market?

Respiratory Biomarker Testing Devices Breakdown Clinical Care Location

Respiratory Biomarker Testing Devices Breakdown Clinical Care Location | Source: Fact.MR

Sales of allergy and immunology settings account for 31.0% of respiratory biomarker testing devices revenue in 2026, about USD 96.2 million, as allergists use breath biomarkers to identify type 2 airway inflammation in patients with allergic rhinitis and asthma. These clinics also screen candidates for biologic therapy. For example, in May 2026, Bedfont Scientific targeted international growth for its NObreath FeNO device at the EAACI Congress, Europe's main allergy and clinical immunology meeting. Similar specialist demand is projected to keep allergy and immunology the leading care location.

Why do service subscriptions lead consumable models in the Respiratory Biomarker Testing Devices Market?

Respiratory Biomarker Testing Devices Breakdown Device Consumable Model

Respiratory Biomarker Testing Devices Breakdown Device Consumable Model | Source: Fact.MR

Service subscriptions to represent 28.0% of respiratory biomarker testing devices revenue in 2026, about USD 86.9 million, as clinics and laboratories pay for devices, analysis, software and support through a single contract. Subscription models suit breath VOC testing, where samples are often sent to central laboratories, and connected FeNO platforms. Manufacturers of biomarker testing devices are packaging sampling kits, analysis and reporting into per-patient or monthly fees. Similar procurement preferences are projected to keep service subscriptions the leading consumable model.

How is diagnostic evaluation shaping patient demand in the Respiratory Biomarker Testing Devices Market?

Respiratory Biomarker Testing Devices Breakdown Patient Use Profile

Respiratory Biomarker Testing Devices Breakdown Patient Use Profile | Source: Fact.MR

Diagnostic evaluation accounts for 27.4% of respiratory biomarker testing devices revenue in 2026, about USD 85.0 million, as clinicians use biomarkers to confirm or rule out asthma, distinguish inflammatory phenotypes and decide on referral. Objective tests reduce misdiagnosis that leads to unnecessary or missing treatment. Manufacturers of biomarker testing devices are publishing decision thresholds and integrating results with asthma management FeNO devices and records. Similar focus on accurate diagnosis is projected to keep diagnostic evaluation the leading use profile.

Respiratory Biomarker Testing Devices Market-Drivers, Restraints & Trends

Drivers

 Demand for respiratory biomarker testing devices is rising as global respiratory bodies push for earlier diagnosis. For example, in October 2026, the Global Initiative for Chronic Obstructive Lung Disease set 'Early diagnosis and treatment for a better life' as the theme for World COPD Day on 18 November 2026, highlighting extensive under- and misdiagnosis. Manufacturers of biomarker testing devices are positioning breath tests to support earlier detection alongside spirometry. Similar awareness campaigns are projected to drive sales of respiratory biomarker testing devices through the forecast period.

Restraints

 Demand for respiratory biomarker testing devices is constrained by limited validation for many emerging breath markers and by slow inclusion in reimbursement schedules. Beyond FeNO and exhaled carbon monoxide, few breath biomarkers have established clinical thresholds accepted in guidelines. Similar evidence gaps are projected to slow routine use of respiratory biomarker testing devices outside research and specialist clinics. Manufacturers of biomarker testing devices must fund prospective studies and work with guideline bodies to move new markers into practice.

Opportunity

 Diagnostic Services Consolidating Under Single Brands In November 2026, Vitalograph announced that Morgan Scientific had become Vitalograph after what it called two years of unprecedented growth in pulmonary function testing. Demand for integrated respiratory diagnostics is rising as clinics prefer one supplier for spirometry, lung function and biomarker testing. Similar consolidation is projected to drive sales of respiratory biomarker testing devices sold within broader diagnostic portfolios. Manufacturers of biomarker testing devices are partnering with lung-function vendors to reach the same buyers.

Trend

Underdiagnosed COPD as a Testing Opportunity Demand for faster respiratory assessment is rising as clinicians confront the scale of undiagnosed COPD. Manufacturers of biomarker testing devices are developing tools that can flag patients for spirometry and specialist review. For example, in November 2026, respiratory specialist Alvar Agustí told HCPLive that about 70% to 80% of COPD patients worldwide are not diagnosed. Similar diagnostic gaps are projected to drive sales of respiratory biomarker testing devices that feed into digital respiratory devices and care pathways.

Respiratory Biomarker Testing Devices Market by Analysis by Key Country

Respiratory Biomarker Testing Devices Growth Index

Respiratory Biomarker Testing Devices Growth Index | Source: Fact.MR

Country CAGR (2026-2036)
China 13.7%
United States 11.6%
Germany 11.1%
United Kingdom 10.3%
Japan 9.4%

Source: Fact.MR analysis. Updated Nov 20, 2026

Source: Fact.MR analysis.

What is driving respiratory biomarker testing devices demand in China?

In November 2026, Chinese specialists published an expert consensus on targeted biologic therapy for inflammatory airway diseases (2026 edition), setting out 15 recommendations on mechanisms, efficacy and safety.

Demand for respiratory biomarker testing devices in China is projected to grow at a 13.7% CAGR, the fastest among the five key countries, as biologic use depends on identifying inflammatory phenotypes. Manufacturers of biomarker testing devices are expanding in tertiary hospitals and respiratory centers. Similar specialist guidance is projected to drive sales of respiratory biomarker testing devices in China.

How is diagnostics growth supporting respiratory biomarker testing devices sales in the United States?

Sales of respiratory biomarker testing devices in the United States are projected to grow at an 11.6% CAGR as pulmonology and allergy practices invest in diagnostic capacity.

For example, in November 2026, Massachusetts- and Ireland-based Vitalograph reported two years of unprecedented growth in pulmonary function testing as Morgan Scientific adopted the Vitalograph name. Manufacturers of biomarker testing devices are selling breath tests alongside lung-function systems to U.S. practices. Similar diagnostic investment is projected to drive sales in the United States.

Why is COPD shaping respiratory biomarker testing devices demand in Germany?

Demand for respiratory biomarker testing devices in Germany is estimated to record a 11.1% CAGR as COPD care focuses on earlier detection.

In November 2026, ahead of World COPD Day, digital health company Breathment highlighted that more than three million people in Germany live with COPD. Manufacturers of biomarker testing devices are serving pulmonology practices and rehabilitation providers with breath and inflammation tests. Similar disease burden is projected to sustain sales of respiratory biomarker testing devices in Germany.

What is shaping respiratory biomarker testing devices demand in the United Kingdom?

Sales of respiratory biomarker testing devices in the United Kingdom are projected to grow at a 10.3% CAGR as NHS pathways use biomarkers to guide referral.

For example, a revised NHS Scotland asthma primary-care pathway published in January 2026 advised considering direct specialist referral for patients with FeNO above 50 parts per billion, where available in primary care. Manufacturers of biomarker testing devices are supporting practices that adopt these thresholds. Similar pathway changes are projected to drive sales in the United Kingdom.

How are new airway therapies shaping respiratory biomarker testing devices demand in Japan?

Demand for respiratory biomarker testing devices in Japan is anticipated to grow at a 9.4% CAGR, the slowest among the five countries, as new airway treatments arrive in a mature market.

In October 2026, brensocatib was launched in Japan for non-cystic fibrosis bronchiectasis, adding to treatments that depend on careful airway assessment. Manufacturers of biomarker testing devices are positioning breath and inflammation testing for Japanese respiratory clinics. Similar therapy launches are projected to support sales in Japan.

Competitive Landscape for Respiratory Biomarker Testing Devices Market

Competition in the respiratory biomarker testing devices market is divided between FeNO and breath CO specialists and emerging breath VOC platforms. NIOX Group and Bedfont Scientific lead in FeNO and carbon monoxide testing, Bosch Healthcare Solutions competes through Vivatmo, Eco Medics and Sunvou Medical Electronics through clinical and research analyzers, and Vitalograph through respiratory diagnostics and trial services, while breath VOC developers such as Owlstone Medical build multi-marker platforms. Buyers select suppliers on clinical validation, cost per test, workflow fit and data integration.

From 2025 onward, competition shifted toward broader portfolios and earlier diagnosis. Vitalograph consolidated Morgan Scientific under its brand in November 2026, Bedfont pursued international growth through allergy congresses, and global COPD campaigns emphasized underdiagnosis. Manufacturers that combine validated biomarkers with lung-function testing and connected reporting are best placed to win specialist and primary-care contracts.

Recent Developments

  • In November 2026, Vitalograph announced that Morgan Scientific had become Vitalograph.
  • In November 2026, Chinese specialists published an expert consensus on targeted biologic therapy for inflammatory airway diseases (2026 edition).
  • In October 2026, GOLD announced 'Early diagnosis and treatment for a better life' as the World COPD Day 2026 theme.
  • In May 2026, Bedfont Scientific targeted international growth for NObreath at the EAACI Congress 2026.

Key Players in Respiratory Biomarker Testing Devices Market

Key companies profiled include NIOX Group plc; Bedfont Scientific Ltd.; ECO MEDICS AG; Bosch Healthcare Solutions GmbH; Sunvou Medical Electronics Co., Ltd.; and MGC Diagnostics Corporation.

  • NIOX Group plc
  • Bedfont Scientific Ltd.
  • ECO MEDICS AG
  • Bosch Healthcare Solutions GmbH
  • Sunvou Medical Electronics Co., Ltd.
  • MGC Diagnostics Corporation

Bibliography

Market Breakdown

Segmentation

Scope of Report

Respiratory Biomarker Testing Devices Taxonomy

Respiratory Biomarker Testing Devices Taxonomy | Source: Fact.MR

Items Values
Quantitative Units (2026) USD 310.2 Million
Biomarker Analyte Breath VOC, Exhaled CO, FeNO, Exhaled breath condensate, Multi-biomarker
Clinical Care Location Allergy / immunology, Pulmonology clinic, Primary care, Pediatric care, Home / remote
Consumable Model Service subscription, Disposable cartridge, Single-use mouthpiece, Calibration gas / kit, Reusable sensor
Patient Use Profile Diagnostic evaluation, Pediatric asthma, COPD, Adult asthma, Longitudinal monitoring
Regions Covered North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East & Africa
Countries Covered China, United States, Germany, United Kingdom, Japan, and other countries
Key Companies Profiled NIOX Group plc; Bedfont Scientific Ltd.; ECO MEDICS AG; Bosch Healthcare Solutions GmbH; Sunvou Medical Electronics Co., Ltd.; MGC Diagnostics Corporation
Additional Attributes Dollar revenue in the Respiratory Biomarker Testing Devices Market is segmented by biomarker analyte (breath VOC, exhaled CO, FeNO, exhaled breath condensate, multi-biomarker), clinical care location, consumable model, patient use profile and region.

Source: Fact.MR analysis. Updated Nov 20, 2026

Respiratory Biomarker Testing Devices Market by Segments

  • Biomarker Analyte

    • Breath VOC
    • Exhaled CO
    • FeNO
    • Exhaled breath condensate
    • Multi-biomarker
  • Clinical Care Location

    • Allergy / immunology
    • Pulmonology clinic
    • Primary care
    • Pediatric care
    • Home / remote
  • Consumable Model

    • Service subscription
    • Disposable cartridge
    • Single-use mouthpiece
    • Calibration gas / kit
    • Reusable sensor
  • Patient Use Profile

    • Diagnostic evaluation
    • Pediatric asthma
    • COPD
    • Adult asthma
    • Longitudinal monitoring
  • Region:

    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of Middle East & Africa
Questions Answered

Frequently Asked Questions

How big is the global Respiratory Biomarker Testing Devices Market in 2026?
The global Respiratory Biomarker Testing Devices Market is valued at USD 310.2 million in 2026.
What will be the size of the Respiratory Biomarker Testing Devices Market by 2036?
The market is projected to reach around USD 902.4 million by 2036.
How fast will the Respiratory Biomarker Testing Devices Market grow during the forecast period?
The market is expected to grow at a CAGR of 11.3% between 2026 and 2036.
Which biomarker analyte segment holds the largest share of the Respiratory Biomarker Testing Devices Market?
Breath VOC holds the largest share, accounting for about 28.1% of total revenue.

Who worked on this report

Preview the report firsthand - request a free sample

Free Sample

Get the brochure for pricing and purchase details

Download PDF
Explore More

Related Reports

Respiratory Biomarker Testing Devices Market

Request a Free Sample

Your personal details are safe with us. Privacy Policy

Share this image

Copy the code below to embed this image, with attribution, on your site.